WASHINGTON -- Biotech drugmaker Amgen said federal health regulators approved its bone-strengthening drug for preventing fractures and skeletal-problems in patients with advanced cancer. The Food and Drug Administration cleared the company's drug denosumab for patients with solid tumors. The FDA approved the drug based on three studies that showed it worked at least as well as Novartis' Zometa ...